Christopher Hill - Core Laboratories Chief Financial Officer, Senior Vice President
CLB Stock | USD 17.08 0.09 0.53% |
President
Mr. Christopher S. Hill has served as Chief Financial Officer of Core Laboratories N.V. since June 25, 2018. He served as Chief Financial Officer, Chief Accounting Officer of the Company between May 18, 2018 and June 25, 2018. He was Senior Vice President, Chief Accounting Officer of the Company between April 30, 2015 and May 18, 2018. Since joining the Company in October 2006, Mr. Hill has held various positions including Corporationrationrate Controller Financial Reporting, Corporationrationrate Group Controller and Investor Relations. Prior to joining the Company, he worked at Halliburton from August 2000 to October 2006 as Controller Energy Chemicals of the KBR Division and Corporationrationrate Director of Training and Accounting Research. Mr. Hill worked at Ernst Young from January 1993 until August 2000, where he held the position of Manager his last three years there since 2018.
Age | 54 |
Tenure | 6 years |
Professional Marks | MBA |
Address | 6316 Windfern Road, Houston, TX, United States, 77040 |
Phone | 713 328 2673 |
Web | https://www.corelab.com |
Core Laboratories Management Efficiency
The company has Return on Asset of 0.0605 % which means that on every $100 spent on assets, it made $0.0605 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1768 %, implying that it generated $0.1768 on every 100 dollars invested. Core Laboratories' management efficiency ratios could be used to measure how well Core Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.21. The current year's Return On Assets is expected to grow to 0.10. At present, Core Laboratories' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 225 M, whereas Total Assets are forecasted to decline to about 550.5 M.Similar Executives
Showing other executives | PRESIDENT Age | ||
Gregg Piontek | Newpark Resources | 53 | |
David Paterson | Newpark Resources | 53 | |
Raymond Chang | Now Inc | 53 | |
Philip Pyle | Enerflex | 58 | |
Roger George | Enerflex | N/A | |
Luca Zanotti | Tenaris SA ADR | 56 | |
Gregory Stewart | Enerflex | 59 | |
Jeffery Juergens | Newpark Resources | 58 | |
Helmuth Witulski | Enerflex | N/A | |
Crystal Gordon | Bristow Group | 41 | |
Mauricio Meineri | Enerflex | N/A | |
David Stepanek | Bristow Group | 58 | |
Toby Eoff | Now Inc | N/A | |
Bruce Smith | Newpark Resources | 66 | |
Matthew Lanigan | Newpark Resources | 53 | |
Jennifer Whalen | Bristow Group | 50 | |
Phillip Vollands | Newpark Resources | 48 | |
Tim Armand | Newpark Resources | N/A | |
Douglas White | Newpark Resources | 51 | |
Edward Earle | Newpark Resources | 51 | |
Mark Johnson | Now Inc | 42 |
Management Performance
Return On Equity | 0.18 | ||||
Return On Asset | 0.0605 |
Core Laboratories Leadership Team
Elected by the shareholders, the Core Laboratories' board of directors comprises two types of representatives: Core Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Core. The board's role is to monitor Core Laboratories' management team and ensure that shareholders' interests are well served. Core Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Core Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
Tahera Khan, Vice President Human Resources | ||
Gwendolyn Schreffler, Senior Vice President, Corporate Development and Investor Relations | ||
Lawrence Bruno, Chairman of the Supervisory Board, President, Chief Executive Officer, Chief Operating Officer | ||
Monique Eeuwijk, Non-Executive Independent Member of the Supervisory Board | ||
D Ogren, Member of the Supervisory Board | ||
Michael Flecker, Vice President Production Enhancement | ||
Christopher Hill, Chief Financial Officer, Senior Vice President | ||
Alastair Crombie, Vice President Reservoir Description | ||
Mark Elvig, Senior Vice President, Secretary, and General Counsel | ||
Harvey Klingensmith, Non-Executive Independent Member of the Supervisory Board | ||
Michael Straughen, Non-Executive Independent Member of the Supervisory Board | ||
John Ogren, Member of the Supervisory Board | ||
Charles Dunlap, Independent Member of the Board of Supervisory Directors | ||
Monty Davis, COO and Sr. VP | ||
David Hume, Vice President Reservoir Description | ||
Gwendolyn MBA, Senior Relations | ||
J Dumas, Vice President Business Development | ||
Martha Carnes, Presiding Non-Executive Lead Independent Member of the Supervisory Board | ||
Richard Bergmark, CFO, Executive VP and Supervisory Director | ||
Kevin Daniels, Vice President, Chief Accounting Officer | ||
Jacobus Schouten, Managing Director | ||
James Gresham, Senior Vice President Business Development | ||
David Demshur, Independent Chairman of the Board of Supervisory Directors and Chief Executive Officer | ||
Kwaku Temeng, Non-Executive Independent Member of the Supervisory Board | ||
Michael Kearney, Independent Supervisory Director | ||
Peter Boks, Vice President Reservoir Description | ||
Gregory Barnett, Non-Executive Independent Member of the Supervisory Board | ||
Chris Hill, Chief Accounting Officer and VP | ||
Margaret Kempen, Independent Member of the Board of Supervisory Directors | ||
Lucia Geuns, Independent Member of the Board of Supervisory Directors | ||
Jeffrey West, Vice President Production Enhancement | ||
Mark Tattoli, Senior Vice President General Counsel, Secretary | ||
Dumas, Vice President Business Development | ||
Gwendolyn Gresham, Senior Vice President Corporate Development and Investor Relations | ||
Jan Sodderland, Independent Member of the Board of Supervisory Directors |
Core Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Core Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.18 | ||||
Return On Asset | 0.0605 | ||||
Profit Margin | 0.07 % | ||||
Operating Margin | 0.13 % | ||||
Current Valuation | 1.01 B | ||||
Shares Outstanding | 46.66 M | ||||
Shares Owned By Insiders | 0.85 % | ||||
Shares Owned By Institutions | 99.15 % | ||||
Number Of Shares Shorted | 5.79 M | ||||
Price To Earning | 101.74 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Core Laboratories in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Core Laboratories' short interest history, or implied volatility extrapolated from Core Laboratories options trading.
Pair Trading with Core Laboratories
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Core Laboratories position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Core Laboratories will appreciate offsetting losses from the drop in the long position's value.Moving together with Core Stock
0.61 | NR | Newpark Resources Financial Report 7th of May 2024 | PairCorr |
Moving against Core Stock
0.57 | NOA | North American Const Financial Report 24th of April 2024 | PairCorr |
The ability to find closely correlated positions to Core Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Core Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Core Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Core Laboratories NV to buy it.
The correlation of Core Laboratories is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Core Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Core Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Core Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Laboratories NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Core Stock analysis
When running Core Laboratories' price analysis, check to measure Core Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Core Laboratories is operating at the current time. Most of Core Laboratories' value examination focuses on studying past and present price action to predict the probability of Core Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Core Laboratories' price. Additionally, you may evaluate how the addition of Core Laboratories to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Core Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Core Laboratories. If investors know Core will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Core Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.72) | Dividend Share 0.04 | Earnings Share 0.51 | Revenue Per Share 10.92 | Quarterly Revenue Growth 0.005 |
The market value of Core Laboratories is measured differently than its book value, which is the value of Core that is recorded on the company's balance sheet. Investors also form their own opinion of Core Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Core Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Core Laboratories' market value can be influenced by many factors that don't directly affect Core Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Core Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Core Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Core Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.